This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Seroquel XR defendants must face ‘supply option’ claims in US antitrust dispute

By Melissa Ritti ( April 3, 2025, 17:50 GMT | Insight) -- Allegations of Sherman Act violations in connection with a 2011 patent settlement where AstraZeneca agreed to supply Handa with generic extended-release quetiapine fumarate — the active ingredient in anti-psychotic drug Seroquel XR — are moving forward in Delaware, following a denial by Chief US Judge Colm F. Connolly of the defendants’ motion for summary judgment.A three-pronged causation challenge by antitrust defendants AstraZeneca Pharmaceuticals LP, AstraZeneca UK Ltd. and Handa Pharmaceuticals has been rejected, with a US judge ruling yesterday the “alternative settlement” theory presented by the expert for a putative end-payor plaintiff class survives summary judgment....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections